Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for Major Depressive Disorder
NCT07908563Phase 2Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial of dupilumab in major depressive disorder (MDD) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Interleukin-4 receptor alpha at Week 9. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07908563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908563.